Rapamycin and HCM in Cats: What the Evidence Shows

Short answer: Hypertrophic cardiomyopathy (HCM) is the most common heart disease in cats — the heart muscle thickens, the chamber fills less efficiently, and most cats show no signs until a crisis. A delayed-release rapamycin formulation studied in cats with subclinical HCM was associated with slower progression of wall thickening. It slows the disease; it does not reverse it. Diagnosis is by echocardiogram, and treatment decisions belong with a veterinary cardiologist.

What HCM actually is

In a healthy heart, the left ventricle is a thin-walled, elastic chamber that fills with blood and pumps it out. In HCM, that wall thickens. A thicker wall sounds stronger, but it is stiffer — the chamber holds less, fills less easily, and the heart has to work harder for less output.

The thickening is not the result of exercise or a strong heart. It is maladaptive remodelling, driven at cellular level by growth signalling that will not switch off.

Why it is so often missed

Cats hide illness, and HCM hides better than most conditions.

There is often no cough, no exercise intolerance you would notice in an indoor cat, no visible warning at all. Roughly a third of cats with HCM have no heart murmur. The first sign, in too many cases, is a catastrophe: sudden congestive heart failure, or an arterial thromboembolism — a clot that lodges where the aorta divides and leaves the hind limbs painful and paralysed.

This is why "my cat seems fine" is not evidence of a healthy heart in a cat of at-risk age or breed.

How it is diagnosed

Echocardiogram is the only definitive test. It measures the wall directly, and a diastolic wall thickness above roughly 6 mm is the usual diagnostic threshold.

Supporting tests raise or lower suspicion but do not confirm: a murmur or gallop rhythm on examination, an elevated NT-proBNP blood test, an enlarged heart silhouette on radiographs. Genetic tests exist for the known Maine Coon and Ragdoll mutations, but a negative genetic test does not rule out HCM.

Where rapamycin comes in

The thickening in HCM is driven by growth signalling, and mTOR is the central pathway that governs whether cells grow or maintain themselves. That makes partial mTOR inhibition a mechanistically sensible target — and rapamycin is the most studied mTOR inhibitor in medicine.

A delayed-release formulation developed for cats was studied in animals with subclinical HCM — disease present, no clinical signs yet. Treated cats showed reduced progression of left ventricular wall thickening compared with placebo, and the formulation subsequently received conditional regulatory approval in the United States for that use.

Two things are worth stating plainly, because marketing in this space often blurs them:

• This is about slowing progression, not reversal. No study has shown a thickened feline heart returning to normal.
• The strongest evidence is in subclinical disease. Cats already in heart failure are a different clinical situation, managed differently.

Within veterinary cardiology this is still notable: for a long time, subclinical HCM had no treatment shown to alter its course at all.

How the protocol works in practice

Dosing for this use is low and intermittent — typically once weekly, with food — rather than the daily immunosuppressive dosing used in transplant medicine. The delayed-release coating protects the molecule through the stomach.

Dose is calibrated to body weight, and monitoring matters: bloodwork before starting, periodic rechecks, and echocardiography to track the wall itself. Cats with concurrent diabetes, active infection, or significant liver disease are generally not candidates.

What this does not mean

It does not mean every cat should be on rapamycin. It does not mean a cat with a murmur should start medication without an echocardiogram. And it does not mean HCM is solved — plenty of cats will still progress.

What it does mean is that "watch and wait" is no longer automatically the only option in subclinical disease, and that is a genuine change worth discussing with a cardiologist.

The honest summary

HCM is common, silent and serious. Screening is the highest-value thing an owner can do, because everything else depends on catching it before a crisis. Rapamycin is the first molecule with evidence of slowing progression in subclinical feline HCM — meaningful, specific, and not the same thing as a cure.